The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | FoRT 05-BEAT: comparing 1L atezolizumab vs atezolizumab + bevacizumab in PD-L1 high NSCLC
Federico Cappuzzo, MD, PhD, AUSL della Romagna-Ravenna, Ravenna, Italy, talks on the rationale behind the Phase III FoRT 05-BEAT (NCT03896074) study comparing atezolizumab versus atezolizumab plus as first-line treatment in patients with PD-L1 high advanced/metastatic non-small cell lung cancer (NSCLC). Strong preclinical evidence suggests that agents interfering with myeloid infiltrates can potentiate the efficacy of immunotherapy. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
